ClinicalTrials.gg
RecruitingNCT06730230Updated Dec 4, 2025

Partners in Control, Phase II: Using Remote Monitoring Technology With Community Health Workers to Support Hypertension Management for Latinx Patients

An interventional study of Remote Patient Monitoring (RPM)-enabled Community Health Worker (CHW) Support in Hypertension, sponsored by NYU Langone Health. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Hypertension by NYU Langone Health — 6 open to participants now, 7 under way, none of them phase 3. Hypertension · NYU Langone Health.

Planned enrollment
20th of 39
300 · median 300
Started
2025
with 2 others
No phase
31 of 44
6 open now
Registered
43rd of 44
by date

Among the 44 studies in Hypertension by NYU Langone Health, this one is the 20th largest by planned enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2025, is one of 31 with no phase, and was the 43rd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 44 studies in Hypertension by NYU Langone Health are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Hypertension by NYU Langone Health, or all of them as a file.
02

Study summary

This study seeks to evaluate the impact of a remote patient monitoring (RPM)-specific tech-enabled community health worker workforce on the use of RPM for the management of hypertension among Latinx patients. This study is a step-wedge randomized controlled trial that aims to assess the effectiveness and implementation of RPM-enabled community health workers (CHWs) compared to standard of care RPM hypertension management on blood pressure reduction and evaluate the implementation of the RPM-enabled CHWs for hypertension (HTN) management. The study aims to examine adoption, acceptability, fidelity, cost, sustainability, and equity as outcomes of implementation effectiveness.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Self-identify as Latinx
  2. Be fluent in English or Spanish
  3. Be age 18 years or older
  4. Receiving care at one of the 10 safety-net primary care clinics
  5. Have uncontrolled HTN documented in the electronic health record (EHR) on at least two visits in the past year (defined as an average BP ≥ 140/90 mmHg)
  6. Have been prescribed at least one anti-hypertensive medication and be non-adherent to their medications, defined as adherence \<80% in the preceding 12 months, as determined by prescription orders obtained from the clinic EHR.

Exclusion criteria

Exclusion Criteria:

  1. Being deemed unable to comply with the study protocol (either self-selected or by indicating during screening that s/he could not complete all requested tasks)
  2. Participation in other hypertension-related clinical trials
  3. Have significant psychiatric comorbidity or reports of substance abuse (as documented in the EHR)
  4. Plan to discontinue care at the clinic within the next 15 months
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Latinx patients with uncontrolled hypertension (HTN)

    Patients will be exposed to the RPM-enabled CHW support, this will be carried out through the step-wedge design, meaning that over the course of the study (\~18 months), all clinics will carry out standard HTN care and also have exposure to the intervention (though at varying time intervals).

    Behavioral: Remote Patient Monitoring (RPM)-enabled Community Health Worker (CHW) Support

Interventions

  • BehavioralRemote Patient Monitoring (RPM)-enabled Community Health Worker (CHW) Support

    CHWs will implement RPM by being provided with training modules and implementing electronic health record (EHR) support tools for HTN management.

06

What researchers measure

Primary outcomes

  1. Change in systolic blood pressure

    Time frame: Baseline, Month 18

  2. Change in diastolic blood pressure

    Time frame: Baseline, Month 18

Secondary outcomes

  1. Rate of hypertension control

    Outcome measure will be assessed using the National Quality Forum-defined thresholds for controlled/uncontrolled hypertension (BP\<140/90 mmHg).

    Time frame: Month 18

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: Devin.Mann@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will be provided access upon reasonable request. Requests should be directed to Devin.Mann@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for May 2026, 15 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 15 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Dec 12, 2024
StartActual
Feb 10, 2025
Primary completionEst.
May 31, 2026
CompletionEst.
May 31, 2027
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06730230
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Dec 12, 2024
Start date
Feb 10, 2025
Primary completion
May 31, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Dec 4, 2025

Study contacts

Devin Mann, MD
Contact
Devin.Mann@nyulangone.org
212-263-8313
Tiffany Martinez
Contact
Tiffany.Martinez@nyulangone.org
646-501-2505
Devin Mann, MD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion